Disc Medicine (IRON) Share-based Compensation (2020 - 2026)
Disc Medicine's (IRON) quarterly Share-based Compensation came in at $11.9 million in Q1 2026, up 87.74% year-on-year from $6.4 million in Q1 2025, and up 18.95% on a QoQ basis from $10.0 million in Q4 2025.
Disc Medicine (IRON) Share-based Compensation (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has 7 years of Share-based Compensation data on file, last reported at $11.9 million in Q1 2026.
- On a quarterly basis, Share-based Compensation rose 87.74% year-over-year to $11.9 million in Q1 2026; TTM through Mar 2026 was $39.9 million, a 108.8% increase from a year earlier, with the FY2025 full-year figure at $101.8 million, up 97.36% from the prior year.
- Share-based Compensation for Q1 2026 stood at $11.9 million, up from $10.0 million in the prior quarter.
- Over the last five years, Share-based Compensation for IRON reached as high as $11.9 million in Q1 2026 and fell as low as $332000.0 in Q1 2022.
- Historically, Share-based Compensation has averaged $4.3 million across 5 years, with a median of $4.1 million in 2024.
- Across the five-year window, Share-based Compensation slumped 86.65% in 2022 and surged 345.52% in 2023, its largest moves.
- Year by year, Share-based Compensation stood at $993000.0 in 2022, then jumped by 345.52% to $4.4 million in 2023, then fell by 2.03% to $4.3 million in 2024, then surged by 131.73% to $10.0 million in 2025, then climbed by 18.95% to $11.9 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $11.9 million in Q1 2026, $10.0 million in Q4 2025, and $9.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Disc Medicine | 2.90 Bn | 2.90 Bn | - | 11.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.95 Mn |
| Mar 31, 2026 | 11.95 Mn |
| Dec 31, 2025 | 10.04 Mn |
| Dec 31, 2025 | 10.04 Mn |
| Sep 30, 2025 | 9.51 Mn |
| Sep 30, 2025 | 9.51 Mn |
| Jun 30, 2025 | 8.42 Mn |
| Jun 30, 2025 | 8.42 Mn |
| Mar 31, 2025 | 6.36 Mn |
| Mar 31, 2025 | 6.36 Mn |
| Dec 31, 2024 | 4.33 Mn |
| Dec 31, 2024 | 4.33 Mn |
| Sep 30, 2024 | 4.33 Mn |
| Sep 30, 2024 | 4.33 Mn |
| Jun 30, 2024 | 4.09 Mn |
| Jun 30, 2024 | 4.09 Mn |
| Mar 31, 2024 | 4.06 Mn |
| Mar 31, 2024 | 4.06 Mn |
| Dec 31, 2023 | 4.42 Mn |
| Dec 31, 2023 | 4.42 Mn |